SEP-363856, a novel non-D2-receptor-binding medication, was found to be effective in a recent psychopharmacological research for the treatment of schizophrenia. The chemical is a full agonist for the trace amine-associated receptor 1 (TAAR1) as well as a partial agonist for the 5-hydroxytryptamin 1A (5-HT 1A) receptor. The TAAR1 ligand neuron, D-neuron, was discovered in the striatum and nucleus accumbens (Acc), a neuroleptic active location, in the human brain, but not in the monkey brain’s analogous area. A total of 154 post-mortem brains were used to research human D-neuron functions, and a modified immunohistochemistry approach using high-quality antibodies against monoamine-related chemicals was used. In post-mortem brains with schizophrenia, the number of D-neuron in the caudate nucleus, putamen, and Acc was reduced. In Acc., the drop was statistically significant (p0.05). I suggested the “D-cell hypothesis of schizophrenia,” which states that NSC dysfunction-based D-neuron decrease represents the cellular and molecular foundation of mesolimbic dopamine (DA) hyperactivity, progressive pathogenesis, and the therapeutic potential of TAAR1.
Department of Psychiatry, Iwaki City Medical Center, Iwaki, Japan.